Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Novel Anticancer Drug Restores Tumor Cell Apoptotic Pathways

By BiotechDaily International staff writers
Posted on 29 Apr 2013
Print article
Image: Dr. Guillaume Lessene (above) and his collaborators have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients (Photo courtesy of Walter and Eliza Hall Institute, Australia).
Image: Dr. Guillaume Lessene (above) and his collaborators have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients (Photo courtesy of Walter and Eliza Hall Institute, Australia).
Cancer researchers have developed a drug that blocks a prosurvival gene in cancer cells and renders them vulnerable to elimination from the body by classical cell death (apoptotic) pathways.

The prosurvival protein BCL-XL is often overexpressed in solid tumors and it renders malignant tumor cells resistant to anticancer therapeutics. BCL-XL (B-cell lymphoma-extra-large) is a transmembrane molecule in the mitochondria. It is a member of the BCL-2 family of proteins, and acts as a prosurvival protein by preventing the release of mitochondrial contents such as cytochrome c, which would lead to caspase activation. BCL-2 (B-cell lymphoma 2) was the founding member of the BCL-2 family of apoptosis regulator proteins encoded by the gene of the same name. The formal name for BCL-2 is B-cell lymphoma 2, as it was the second member of a range of proteins initially described in chromosomal translocations involving chromosomes 14 and 18 in follicular lymphomas.

Investigators at the Walter and Eliza Hall Institute (Victoria, Australia) and their colleagues at the biotech company Genentech (San Francisco, CA, USA) sought to develop a drug that would inhibit specifically BCL-XL without affecting other BCL-2 family proteins.

To this end, they employed a high-throughput screen to discover a new series of small molecules targeting BCL-XL and then used this structure to guide development of the drug by medicinal chemistry. They reported in the April 21, 2013, online edition of the journal Nature Chemical Biology that the optimized compound, WEHI-539, had high affinity (subnanomolar range) and selectivity for BCL-XL and potently killed cells by selectively antagonizing its prosurvival activity. WEHI-539 was found to belong to the class of anti-cancer drugs called "BH3-mimetics.” Other drugs in this class include navitoclax (ABT-263) and ABT-199/GDC-0199, which are currently in clinical trials for the treatment leukemia and lymphoma.

Senior author Dr. Guillaume Lessene, professor of chemical biology at the Walter and Eliza Hall Institute, said, "That the development of WEHI-539 was an important milestone on the way to creating potential anticancer agents that act to restore cell death by inhibiting BCL-XL. Although WEHI-539 is not optimized for use in patients, it will be a very valuable tool for researchers to use to dissect how BCL-XL controls cancer cell survival."

"We were very excited to see the team's work culminate in a compound that specifically inhibits BCL-XL," said Dr. Lessene. "WEHI-539 is the first compound that our chemists have developed from scratch, using the three-dimensional structure of BCL-XL to build and refine its design."

Related Links:

Walter and Eliza Hall Institute
Genentech



Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.